Research Overview
PT-141, also catalogued as Bremelanotide, is a synthetic cyclic heptapeptide investigated in central nervous-system pathway research. The compound is presented as a lyophilized white powder in a 10 mg vial under CAS 189691-06-3 with a measured purity of 99.664% by HPLC. Its sequence is Ac-Nle-c[Asp-His-D-Phe-Arg-Trp-Lys]-OH and molecular weight 1024.1 Da.
PT-141 is a melanocortin receptor-binding research compound studied in preclinical investigations focused on the melanocortin-4 receptor and downstream hypothalamic circuits. Unlike Melanotan II, PT-141 was developed as a selective analog with modifications intended to improve receptor-targeting characteristics in laboratory models.
Each vial supplied by Origin Research ships with a Certificate of Analysis, including HPLC chromatogram and mass spectrometry data. The product is intended strictly for laboratory research and is not approved for human or veterinary administration.
Mechanism Studied in Research
PT-141 has been characterized in receptor-binding research as a melanocortin-system agonist. Experimental literature has evaluated interactions with MC4R and related receptor families involved in neurological signaling pathways. Research models have investigated how melanocortin receptor activation influences downstream neurobehavioral responses and central nervous-system regulation.
Studies examining PT-141 frequently focus on receptor occupancy, signal-transduction pathways, and comparative activity versus earlier melanocortin analogs. Investigators continue to explore the compound’s pharmacological profile in laboratory environments designed to evaluate melanocortin-mediated biological mechanisms.
Research Applications
PT-141 is widely utilized in laboratory investigations involving melanocortin signaling, receptor pharmacology, and neurobehavioral pathway research. Experimental studies frequently examine receptor selectivity, downstream signaling effects, and comparative performance among melanocortin-family compounds.
Researchers also employ PT-141 in preclinical models evaluating central nervous-system mechanisms and receptor-mediated responses. Additional applications include pathway-mapping studies, pharmacodynamic investigations, and comparative analyses involving MC4R-targeted research compounds.
Reconstitution Reference
PT-141 is supplied as a lyophilized powder and is commonly reconstituted using bacteriostatic water under laboratory conditions. Researchers frequently add 1–2 mL of bacteriostatic water depending on study design and target stock concentration.
The diluent should be introduced slowly against the vial wall while avoiding direct impact on the peptide cake. Following complete dissolution, researchers typically record dilution volume, concentration calculations, and batch information according to laboratory documentation procedures.
Storage and Handling
Lyophilized PT-141 should be stored at -20°C and protected from light and moisture until use. Short-term refrigerated storage at 2–8°C may be acceptable for limited periods under validated laboratory conditions.
Following reconstitution, solutions are generally maintained under refrigerated conditions and handled according to institutional laboratory protocols. Researchers should document storage conditions, reconstitution dates, and handling procedures according to laboratory traceability requirements.
References
[2] (2006). An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide. PMID 16527729
[3] (2007). Bremelanotide for female sexual dysfunction in premenopausal women. PMID 17609297
[4] (2008). Potent and selective agonism of the melanocortin receptor 4 with MC4R-005 does not induce weight loss in obese human subjects. PMID 18515470
[5] (2003). PT-141: a melanocortin agonist for the treatment of sexual dysfunction. PMID 12851327